Investigating Notch ligands as drivers of T-cell lymphomas and potential treatment targets
Official title: Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomas
Funded at University of Michigan at Ann Arbor · NIH-11005318 · Data updated 2026-11-12
This study is looking at a type of aggressive cancer called peripheral T-cell lymphoma to see how a specific signaling process in the body affects its growth, with the hope of finding new treatment options that could help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $621,443 |
| NIH project number | 5R01CA278976-02 |
| Project ID | NIH-11005318 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with peripheral T-cell lymphomas, particularly those who have relapsed or are refractory to existing treatments.
✕Less likely to help
Patients with other types of lymphomas or those who do not have T-cell lymphomas may not benefit from this research.
What this research studies
This research focuses on peripheral T-cell lymphomas (PTCL), which are aggressive cancers originating from mature T cells. The study aims to understand how Notch signaling, influenced by the tumor microenvironment, contributes to the growth and survival of these lymphomas. By using genetically engineered mouse models and primary patient samples, researchers will explore the role of Notch ligands in PTCL and identify potential therapeutic strategies that could improve patient outcomes. The goal is to uncover new treatment options that target the specific mechanisms driving these cancers.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with aggressive T-cell lymphomas, potentially improving survival rates.
How similar studies have gone: Previous research has shown promise in targeting Notch signaling in various cancers, suggesting that this approach may yield beneficial results for T-cell lymphomas as well.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Wilcox, Ryan a — University of Michigan at Ann Arbor
- Study coordinator: Wilcox, Ryan a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.